Fig. 4

Correlation analysis of Tyro3TK on CD14⁺CD16⁻ monocytes with RA patient clinical manifestations. The associations of Tyro3TK on CD14⁺CD16⁻ monocytes with RA patient DAS28-ESR (r = 0.323, *P = 0.042) (a), tender joint counts (TJC) (r = 0.514, **P = 0.001) (b), and IgM (r = 0.432, **P = 0.005) (c) were analyzed. The expression of Tyro3TK on CD14⁺CD16⁻ monocytes were also compared between the different RA patient groups: d RA with high disease activity (DAS28-ESR > 5.1) and non-high disease activity (DAS28-ESR ≤ 5.1) (*P = 0.034), e RA with and without tender joints (*P = 0.031), f rheumatoid factor (RF) positive and negative RA (*P = 0.024), g anti-CCP antibody positive and negative RA, h male and female RA, and i RA with and without swollen joints. *P < 0.05, **P < 0.01; ns, not significant (Spearman’s rank correlation test, a–c; Mann-Whitney U test, d–i)